FN1 and Salla disease: Corresponding histological analyses confirmed enhanced EDB-FN expression and reduced cell density in SD tumors compared to non-responders (Figure 3B), validating the MT218-MRMI data (Figure S5) particularly at the two weeks post-treatment initiation time point.